Inflammation has emerged as a key component of the metabolic syndrome. The canonical NF-κB pathway is a well-studied regulator of inflammatory processes and is heavily implicated in insulin resistance and β cell dysfunction in diabetes. Inhibition of NF-κB improved glucose tolerance in human and animal studies ([@bib59]; [@bib27]; [@bib20]). The IκB-like kinases IKK-ε and TANK-binding kinase (TBK1) are downstream NF-κB targets involved in driving insulin resistance ([@bib10]) and blockade of IKK-ε and TBK1 improves metabolic function in obesity ([@bib44]). Thus, canonical NF-κB is a central molecular pathway in obesity-dependent changes in the metabolic syndrome.

A divergent arm of NF-κB signaling is the noncanonical NF-κB pathway mediated by NF-κB--inducing kinase (NIK), which is activated downstream of TNF receptor (TNFR) family members including TNFR2, receptor activator of NF-κB (RANK), lymphotoxin β receptor (LTβR), or CD40 upon ligand binding ([@bib48]). NIK levels and hence its activation are controlled by an E3 ligase complex; TNFR-associated factor 2 (TRAF2) recruits the E3 ligases baculoviral IAP repeat-containing proteins 2 and 3 (BIRC2/3), whereas interactions with TRAF3 allows delivery of NIK to the complex ([@bib51]; [@bib61]). In the absence of a ligand, NIK is ubiquitinated by this complex and targeted for proteasome-dependent degradation, thereby silencing the noncanonical NF-κB pathway ([@bib51]; [@bib61]). The noncanonical NF-κB dimer regulates gene expression through binding to general, as well as specific, noncanonical κB target sites ([@bib4]); however, its targets and the phenotypic consequence of its activation are incompletely known. Studies show that noncanonical NF-κB pathway activation mediated through loss of TRAF2 or TRAF3 promotes expansion of B cells ([@bib18]), and leads to a shift in the proportions of specific T cell subpopulations ([@bib57]). Recently, activation of the noncanonical NF-κB pathway has been linked to the metabolic syndrome ([@bib11]; [@bib46]; [@bib31]). For example, NIK levels are high in muscle biopsies of obese patients, but decline after gastric bypass surgery, weight loss, and a decrease in insulin resistance ([@bib11]).

Emerging evidence emphasizes a crucial role for pancreatic β cell dysfunction in type 2 diabetes (T2D). Genome-wide association studies (GWAS) have identified a large number of loci associated with β cell function and survival ([@bib16]; [@bib23]; [@bib49]). Further, hyperglycemia ([@bib14]), circulating inflammatory factors ([@bib47]), or amyloid production in the islet ([@bib53]) are deleterious for islets and contribute to T2D pathogenesis. This is indicated by diminished β cell mass ([@bib6]), but also by reduced β cell secretory function in T2D patients ([@bib15]). Thus, β cell dysfunction in diabetes pathogenesis is now being acknowledged as a critical and major contributor in diabetes pathogenesis. However, the mechanisms for loss of β cell function and mass are incompletely known. Therefore, it is essential to elucidate factors that contribute to both insulin resistance in peripheral tissue and β cell failure.

Core components of the noncanonical NF-κB pathway have been identified in pancreatic islets ([@bib39]); however, the functional consequence of NIK and subsequent noncanonical NF-κB activation in β cells is completely unknown. We demonstrate here that pharmacologically induced NIK disrupts glucose homeostasis in vivo in a zebrafish model and impairs glucose-stimulated insulin secretion in mouse and human islets. Additionally, a high-fat diet triggers β cell--intrinsic NIK activation and disruption of the E3 ligase control circuit regulating NIK impairs β cell insulin secretory capacity in a diet-induced obesity model in mice. Here, for the first time, we demonstrate a novel function for NIK and subsequent noncanonical NF-κB activation as a negative regulator of pancreatic β cell function, impairing insulin secretion in diet-induced obesity. NIK activation in the metabolic syndrome is a feature of pancreatic β cells but also insulin-dependent peripheral tissues, thereby providing a tissue-spanning mechanism to link inflammation with multiple tissue failure in diabetes pathogenesis.

RESULTS
=======

Systemic monovalent 1 (MV1) administration impairs glucose homeostasis in zebrafish in vivo
-------------------------------------------------------------------------------------------

Aberrant BIRC function has been associated with many human cancers ([@bib17]), leading to the development of a group of peptide-derived drugs called second mitochondria-derived activator of caspase (SMAC) mimetics, which induce the degradation of BIRC2 and BIRC3, thereby interfering with their ability to inhibit apoptosis ([@bib52]). Concomitantly, degradation of BIRC2 and BIRC3 elicits NIK accumulation, which leads to proteasome-dependent processing of p100 into p52 and hence activates the noncanonical NF-κB pathway ([@bib52]).

To test whether systemic elevation of NIK mediated by the SMAC mimetic MV1 would alter glucose homeostasis in vivo, we used a zebrafish model. The main organs required for metabolic control, such as the pancreas, islet, and insulin-sensitive tissue (muscle, liver) are conserved in zebrafish, rendering it an excellent model to study glucose homeostasis ([@bib24]; [@bib29]; [@bib45]). First, we showed that synthesized MV1 could induce NIK accumulation and processing of p100 into p52 in MDA-MB-231/Luc breast cancer cells, indicating activation of noncanonical NF-κB signaling ([Fig. 1 A](#fig1){ref-type="fig"}), as described previously ([@bib52]). We next injected MV1 into zebrafish larvae at 6 d postfertilization (dpf) and examined glucose levels after 6 h. WT larvae treated with MV1 exhibited increased glucose levels compared with vehicle (DMSO) controls ([Fig. 1 B](#fig1){ref-type="fig"}). This indicates that MV1-induced NIK activation disrupts glucose homeostasis in vivo in WT zebrafish.

![**MV1 disrupts glucose homeostasis in zebrafish and impairs β cell function in human and mouse islets.** (A) Protein levels of NIK and p100 to p52 processing in the MDA-MB-231/Luc breast cancer cell line treated with increasing concentrations of MV1 were assessed by immunoblotting. A representative of four independent experiments is shown. Histogram data depicts cumulative densitometry relative to β-actin of the four independent experiments. (B) Glucose levels in zebrafish larvae injected with DMSO or MV1 were assessed. The data are mean and SEM derived from seven control and five MV1-treated groups, with four larvae per group, in a representative of two independent experiments. \*\*, P \< 0.01. (C) Protein levels of p100 to p52 processing in DMSO and MV1-treated C57BL/6 mouse islets from one islet isolate were assessed by immunoblotting. A representative of three independent experiments is shown. Histogram data depicts cumulative densitometry relative to β-actin of the three independent experiments. (D) In vitro GSIS in 2 and 20 mM [d]{.smallcaps}-glucose and in KCl conditions of DMSO control and MV1-treated primary mouse islets was measured. Data are mean and SEM derived from six independent islet isolates for each group, and are representative of two independent experiments. \*\*, P \< 0.01. (E--G) Blood glucose and AUC were determined in DMSO control and MV1-treated mouse islet C57BL/6 transplant recipients after i.p. injection of [d]{.smallcaps}-glucose at (E) POD 3 (AUC, \*\*, P \< 0.01; control, *n* = 9; MV1, *n* = 8), (F) POD 7 (\*, P \< 0.05; control, *n* = 12; MV1, *n* = 13), and (G) POD 11 (n.s.; control, *n* = 10; MV1, *n* = 10). Data are representative of three independent mouse cohorts tested. (H) H&E staining and insulin immunostaining of DMSO control and MV1-treated mouse islet grafts are shown. Graft β cell area was determined for three DMSO and three MV1-treated islet grafts by quantification of insulin-positive area in continuous serial graft sections. A representative image for each condition is shown. Boxed insets represent magnified area. Differences in graft area are not significant. \*, P \> 0.05. Bar, 100 µm. (I) In vitro GSIS in 2.8 and 25 mM [d]{.smallcaps}-glucose conditions of DMSO control and MV1-treated primary human islets was measured. Data are mean and SEM derived from quintuplets for DMSO and MV1-treated islets and are representative of three independent human islet isolates. \*, P \< 0.05. All data are represented as mean ± SEM; p-values were determined using Student's *t* test.](JEM_20150218_Fig1){#fig1}

MV1 administration activates NIK in mouse and human islets and impairs glucose-stimulated insulin secretion
-----------------------------------------------------------------------------------------------------------

To elucidate whether the defect in glucose homeostasis relates to MV1-induced, NIK-mediated β cell dysfunction, we examined the effect of MV1 on insulin secretion of primary C57BL/6 WT islets. Addition of MV1 to WT islets triggered p100 to p52 processing, indicating NIK activation ([Fig. 1 C](#fig1){ref-type="fig"}). MV1 had no effect on islet survival in 24-h in vitro cultures as assessed by calcein-AM uptake and ethidium homodimer DNA intercalation (unpublished data). In a glucose-stimulated insulin secretion (GSIS) assay, MV1-treated islets exhibited normal basal insulin output, but insulin secretion was reduced by ∼50% compared with controls when challenged with 20 mM glucose. Potassium chloride (KCl)--stimulated secretion was normal, indicating normal insulin content ([Fig. 1 D](#fig1){ref-type="fig"}). To assess the effect of MV1-treatment in vivo, we transplanted either MV1- or vehicle-treated islets into diabetic syngeneic recipients. A glucose tolerance test (GTT) at post-operative day (POD) 3 revealed that, compared with controls, MV1-treated grafts exhibited impaired glucose tolerance ([Fig. 1 E](#fig1){ref-type="fig"}). Glucose tolerance was still slightly impaired at POD 7, but had completely resolved by POD 11 such that MV1-treated islets provided equivalent metabolic control to vehicle treated islets ([Fig. 1, F and G](#fig1){ref-type="fig"}). Further, MV1-treated grafts exhibited normal morphology and insulin staining, as well as equivalent graft area determined by morphometry ([Fig. 1 H](#fig1){ref-type="fig"}). This indicates that acute activation of NIK results in a temporary β cell defect that is reversed upon drug-clearance and suppression of NIK.

NIK activation impairs glucose-stimulated insulin secretion in human islets
---------------------------------------------------------------------------

We next assessed whether β cell--intrinsic activation of NIK would impair the function of human islets. Human islets treated with MV1 showed normal basal (2.8 mM) but defective glucose-stimulated (25 mM) insulin secretion ([Fig. 1 I](#fig1){ref-type="fig"}). Thus, activation of NIK in human islets resulted in impaired β cell function. These data highlight the importance of the NIK pathway and its contribution to β cell dysfunction in human islet physiology.

NIK is activated in islets in diet-induced obesity
--------------------------------------------------

To elucidate whether NIK plays a role in islets in a model of glucose intolerance, a diet-induced obesity (DIO) model, C57BL/6 mice were placed on a 45% kcal high-fat diet (HFD). After 8 wk of HFD, these mice showed impaired glucose tolerance and insulin secretion ([Fig. 2, A and B](#fig2){ref-type="fig"}), increased β cell mass ([Fig. 2 C](#fig2){ref-type="fig"}), and reduced insulin output capacity in fasted conditions and in response to an in vivo glucose challenge ([Fig. 2 D](#fig2){ref-type="fig"}). These results are supported by previous studies ([@bib56]; [@bib40]). Islets from DIO mice exhibited activation of the noncanonical NF-κB pathway ([Fig. 2 E](#fig2){ref-type="fig"}), as indicated by the accumulation of NIK and increased phosphorylation of the NIK downstream target IκB kinase α (IKKα). Activated phospho-IKKα phosphorylates NF-κB p100, leading to its proteasome-dependent cleavage releasing active p52. Islets from DIO mice exhibited a higher processing rate of NF-κB p100 to p52 and increased levels of the p52 binding partner RelB, compared with islets from chow-fed controls. As the antibody for Phospho-IKK not only identifies phospho-IKKα but also phospho-IKKβ, we probed for IKKβ downstream target IκBα, which is the canonical NF-κB inhibitor; IκBα levels were normal, indicating absence of canonical NF-κB activation in DIO islets.

![**Pancreatic islets in a DIO model exhibit NIK hyperactivation and display a net β cell secretory defect.** (A) Blood glucose and AUC were determined in 12 chow (dotted line) and 15 DIO (solid line) fed C57BL/6 WT mice (16 wk old) after i.p. injection of [d]{.smallcaps}-glucose. Data are representative of three independent mouse cohorts tested. \*\*\*\*, P \< 0.0001. (B) Insulin levels and AUC (10 min after injection) were determined for 5 chow (dotted line) and 15 DIO (solid line) fed C57BL/6 WT mice (16 wk old) after i.v. injection of [d]{.smallcaps}-glucose. Data are representative of three independent mouse cohorts tested. \*, P \< 0.05. (C) Total β cell area was determined for 5 chow- and 5 HFD-fed WT mice by quantification of insulin-positive area in serial graft sections as a percentage of total pancreatic exocrine area (\*, P \< 0.05). (D) Data are mean and SEM showing percentage of net insulin secretion normalized to mean β cell area determined for mice in C. (left) Net fasted insulin levels; (right) net secretion (AUC) for 10 min after [d]{.smallcaps}-glucose injection. \*, P \< 0.05; \*\*\*\*, P \< 0.0001. (E) Protein levels of NIK, IKKα/β phosphorylation, IκBα, p100 to p52 processing, and RelB in one islet isolate from a chow-fed and a DIO C57BL/6 WT mouse were assessed by immunoblotting. A representative of four independent experiments is shown. Histogram data depict cumulative densitometry relative to β-actin of the four independent experiments. (F and G) Protein levels of p100 to p52 processing and RelB in one (F) TNF- and (G) RANKL-stimulated mouse islet isolate at 0, 1, and 4 h after stimulation. IκBα levels at 0, 15, 30, 60, and 240 min after stimulation were assessed by immunoblotting. A representative of four independent experiments is shown. Histogram data shows cumulative densitometry relative to β-actin of the four independent experiments. All data are represented as mean ± SEM; p-values were determined using Student's *t* test.](JEM_20150218_Fig2){#fig2}

TNF and RANKL trigger NIK activation in primary islets
------------------------------------------------------

Both TNF and receptor activator of NF-κB ligand (RANKL) activate the noncanonical NF-κB pathway in various cell types, including immune cells ([@bib43]) and osteoclasts ([@bib36]), and high circulating serum levels of TNF and RANKL are associated with diabetes ([@bib26]; [@bib31]). The effect of TNF and RANKL on noncanonical NF-κB signaling in islets is unknown. TNF induced p100 to p52 processing and RelB accumulation in primary mouse islets, indicating NIK activation ([Fig. 2 F](#fig2){ref-type="fig"}). TNF also induced canonical NF-κB activation as shown by degradation of its inhibitor IκBα. RANKL induced p100 to 52 processing and RelB accumulation in primary islets, indicating NIK activation, but did not activate canonical NF-κB signaling ([Fig. 2 G](#fig2){ref-type="fig"}). Therefore, both TNF and RANKL activate NIK signaling in primary mouse islets. Additionally, islets isolated from HFD-fed mice show cell-intrinsic activation of NIK and activation of the noncanonical NF-κB pathway with reduced insulin secretion.

Cell-intrinsic NIK activation negatively regulates β cell function in a model of diet-induced obesity
-----------------------------------------------------------------------------------------------------

The aforementioned data present a causal link between β cell dysfunction and NIK activation in DIO. To test this concept further, we used a genetic approach whereby β cells would express high levels of active NIK in a cell-intrinsic manner. NIK levels, and hence its activation, are controlled by an E3 ligase complex; TRAF2 recruits the E3 ligases BIRC2/3 while interactions with TRAF3 allow delivery of NIK to the complex ([@bib51]; [@bib61]). In absence of a ligand, NIK is ubiquitinated by this complex and targeted for proteasome-dependent degradation thereby silencing the noncanonical NF-κB pathway ([@bib51]; [@bib61]). Deletion of any one component, i.e., TRAF2, TRAF3, or the BIRC proteins, results in cell-intrinsic hyperactivation of noncanonical NF-κB pathway at a physiological level ([@bib18]; [@bib61]).

To examine how β cell--intrinsic NIK activation would affect glucose homeostasis, we generated β cell--specific TRAF2 knockout (βTRAF2) mice. TRAF2~loxP/loxP~ were crossed with mice expressing Cre under the control of the rat insulin promoter (RIP Cre). TRAF2 mRNA and protein were expressed in TRAF2~loxP/loxP~ islets but depleted in islets from βTRAF2 mice ([Fig. 3, A and B](#fig3){ref-type="fig"}). βTRAF2 islets showed high cell-intrinsic accumulation of NIK with hyper-phosphorylation of IKKα ([Fig. 3 C](#fig3){ref-type="fig"}). βTRAF2 islets exhibited increased p100 processing into p52 and higher levels of RelB. In contrast, IκBα levels were not changed in βTRAF2 islets, indicating that IKKβ and canonical NF-κB signaling were not activated. Thus, loss of TRAF2 results in cell-intrinsic constitutive activation of NIK in pancreatic β cells.

![**Constitutive NIK activation elicits a defect in insulin secretion.** (A) TRAF2 protein levels in WT and βTRAF2 islets isolated from one WT and one βTRAF2 mouse assessed by immunoblotting. A representative of three independent islet isolates tested per genotype is shown. Histogram data depicts mean and SEM cumulative densitometry data relative to β-actin of the three independent experiments. (B) Relative expression of islet TRAF2 mRNA from six WT and nine βTRAF2 islet isolates was determined by RT-PCR. Data are representative of two independent experiments. \*\*\*, P \< 0.001. (C) Protein levels of NIK, IKKα/β phosphorylation, IκBα, p100 to p52 processing, and RelB in one nonstimulated WT and one βTRAF2 islet isolate were assessed by immunoblotting. A representative of three independent experiments is shown. Histogram data depicts cumulative densitometry relative to β-actin of the three independent experiments. (D) Non-fasted blood glucose levels were determined in 30 TRAF2~loxP/loxP~ (WT), 10 RI Cre (WT), and 24 βTRAF2 chow-fed mice at 8-wk-old (\*\*\*, P \< 0.001) and in 15 TRAF2~loxP/loxP~ (WT), 5 RI Cre (WT), and 12 βTRAF2 chow-fed mice at 16 wk of age (n.s.) and in 15 TRAF2~loxP/loxP~ (WT), 5 RI Cre (WT), and 12 βTRAF2 HFD-fed mice at 16 wk old (n.s.). Data are representative of three independent mouse cohorts tested. (E) Blood glucose levels were measured in 15 TRAF2~loxP/loxP~ (WT), 5 RI Cre (WT) and 12 βTRAF2 chow-fed mice (16 wk old) after i.p. injection of [d]{.smallcaps}-glucose (WT, dotted line; βTRAF2, solid line). Data are representative of three independent mouse cohorts tested. \*\*, P \< 0.01. (F) Insulin levels were measured in six TRAF2~loxP/loxP~ (WT) and six βTRAF2 chow-fed mice (16 wk old) after i.v. injection of [d]{.smallcaps}-glucose (WT, dotted line; βTRAF2, solid line). Data are representative of three independent mouse cohorts tested (n.s.). (G) Blood glucose levels were measured in 15 TRAF2~loxP/loxP~ (WT), 5 RI Cre (WT), and 12 βTRAF2 HFD-fed mice (16 wk old) after i.p. injection of [d]{.smallcaps}-glucose (WT, dotted line; βTRAF2, solid line). Data are representative of three independent mouse cohorts tested. (\*\*\*, P \< 0.001) (H) Insulin levels were measured in 10 TRAF2~loxP/loxP~ (WT), 5 RI Cre, and 10 βTRAF2 HFD-fed mice (16 wk old) after i.v. injection of [d]{.smallcaps}-glucose (WT, dotted line; βTRAF2, solid line). Data are representative of three independent mouse cohorts tested. \*, P \< 0.05. (I) Pancreatic insulin content in chow- and HFD-fed WT and βTRAF2 mice was determined. The data are mean and SEM derived from five mice per group (chow, n.s.; DIO, \*, P \< 0.05). (J) Total β cell area was determined for chow- and HFD-fed WT and βTRAF2 mice by quantification of insulin-positive area in serial graft sections as a percentage of total pancreatic exocrine tissue. The data are mean and SEM derived from three mice per group (chow, n.s.; DIO, \*, P \< 0.05). (K) Insulin immunohistochemistry of histological pancreatic sections of chow- and HFD-fed WT and βTRAF2 mice is shown. The data are representative images of three mice per group. Bars, 100 µm. (L) *Insulin-1* and *Insulin-2* mRNA expression in chow- and HFD-fed TRAF2~loxP/loxP~ (WT) and βTRAF2 from four (*Ins1*) and five (*Ins2*) islet isolates was determined by RT-PCR and is presented as a fold change relative to WT (n.s.; data are representative of two independent experiments). All data are represented as mean ± SEM; p-values were determined using Student's *t* test.](JEM_20150218_Fig3){#fig3}

Chow-fed βTRAF2 mice exhibited normal weight gain over the experimental period of 8 wk and normal glucose tolerance at 8 wk of age (not depicted). They also had mildly elevated nonfasted blood glucose levels ([Fig. 3 D](#fig3){ref-type="fig"}) compared with floxed littermates and RIP Cre/+ controls. By 16 wk of age, chow-fed βTRAF2 mice showed very mild glucose intolerance ([Fig. 3 E](#fig3){ref-type="fig"}) and no significant difference in insulin secretion ([Fig. 3 F](#fig3){ref-type="fig"}) compared with WT mice. However, in a DIO model, βTRAF2 mice showed greatly exacerbated glucose intolerance compared with WT mice ([Fig. 3 G](#fig3){ref-type="fig"}). We next examined in vivo insulin secretion (i.v. GTT) to test whether this related to a β cell defect. In this experiment, DIO βTRAF2 mice exhibited a reduction in first-phase insulin secretion ([Fig. 3 H](#fig3){ref-type="fig"}). These data demonstrate that β cell--intrinsic activation of NIK results in impaired glucose tolerance due to reduced β cell function.

NIK activation influences β cell mass in a model diet-induced obesity
---------------------------------------------------------------------

To determine whether the reduction in insulin secretion was due to decline in insulin production, we determined total pancreatic insulin content and β cell area. On a chow diet, pancreata from βTRAF2 mice showed similar total insulin content as WT mice and normal β cell area ([Fig. 3, I and J](#fig3){ref-type="fig"}). However, in the DIO model, βTRAF2 mice exhibited increased pancreatic insulin content compared with WT mice ([Fig. 3 I](#fig3){ref-type="fig"}). This is accompanied by an increase in β cell area in DIO βTRAF2 mice ([Fig. 3 J](#fig3){ref-type="fig"}). Also, β cells in βTRAF2 islets exhibited robust insulin expression as determined by insulin immunostaining ([Fig. 3 K](#fig3){ref-type="fig"}) and normal levels of *Insulin-1* and *Insulin-2* determined by RT-PCR ([Fig. 3 L](#fig3){ref-type="fig"}). Thus, we can conclude that β cell--intrinsic NIK activation results in a loss of insulin secretory capacity rather than a defect in insulin production. Additionally, we hypothesize that the increased β cell mass in DIO βTRAF2 mice most likely represents a physiological compensatory response to the reduced insulin secretory capacity of the βTRAF2 islet.

The function of βTRAF2 islets is impaired after transplantation
---------------------------------------------------------------

In the DIO model, βTRAF2 mice presented a blunted first-phase insulin secretion compared with controls. A subset of transgenic RIP Cre mouse lines have been reported to exhibit hypothalamic Cre expression ([@bib55]). To discern between hypothalamus-mediated and islet-specific defects, we isolated pancreatic βTRAF2 and control islets, and transplanted 150 islet equivalents into streptozotocin-treated diabetic syngeneic C57BL/6 recipients. Under these conditions both WT and βTRAF2 islet grafts restored normal metabolic control ([Fig. 4 A](#fig4){ref-type="fig"}). To test β cell function, we performed an i.p. GTT at POD 11. Compared with mice receiving WT islet grafts, βTRAF2 graft recipients exhibited impaired glucose tolerance ([Fig. 4 B](#fig4){ref-type="fig"}). Next, we determined insulin secretion in graft recipients via an i.v. GTT at POD 21. Recipients of βTRAF2 islet grafts exhibited a blunted first-phase insulin secretion compared with mice receiving WT islet grafts ([Fig. 4 C](#fig4){ref-type="fig"}). Graft pathology revealed that βTRAF2 grafts exhibited normal morphology and insulin staining, as well as equivalent graft area determined by morphometry ([Fig. 4 D](#fig4){ref-type="fig"}). Therefore, we conclude that loss of glucose tolerance was not due to β cell loss.

![**Deletion of TRAF2 causes impaired glucose tolerance independent of Cre expression in the hypothalamus.** (A) Non-fasted blood glucose levels in STZ-treated C57BL/6 recipients transplanted with 150 IEQs of WT (dotted line) and βTRAF2 (solid line) islets were determined. Data are representative of three independent mouse cohorts, in which 15 TRAF2~loxP/loxP~ (WT)~,~ 10 RI Cre (WT), and 14 βTRAF2 islet transplant recipients were tested. (B) Blood glucose and AUC were assessed in 8 TRAF2~loxP/loxP~ (WT), 4 RI Cre (WT), and 10 βTRAF2 islet transplant recipients after i.p. injection of [d]{.smallcaps}-glucose at day 11 after transplant. Data are representative of three independent mouse cohorts tested. \*, P \< 0.05. (C) Insulin levels and AUC were assessed in 6 TRAF2~loxP/loxP~ (WT), 4 RI Cre (WT), and 10 βTRAF2 islet transplant recipients after i.v. injection of [d]{.smallcaps}-glucose at day 21 after transplant. Data are representative of three independent mouse cohorts tested. \*, P \< 0.05. (D) H&E staining and insulin immunohistochemistry of WT and βTRAF2 islet grafts are shown. Graft β cell area was determined for three WT and three βTRAF2 islet grafts by quantification of insulin-positive area in continuous serial graft sections. A representative image for each condition is shown. Boxed insets represent magnified area. Differences in graft area are not significant (P \> 0.05). Bar, 100 µm. (E) In vitro GSIS in 2, 11, and 20 mM [d]{.smallcaps}-glucose and in KCl conditions in WT and βTRAF2 mouse islets was measured. Data are mean and SEM derived from six independent islet isolates for each group, and are representative of two independent experiments. \*\*, P \< 0.01. All data are represented as mean ± SEM; p-values were determined using Student's *t* test.](JEM_20150218_Fig4){#fig4}

Ex vivo glucose-stimulated insulin secretion is diminished in βTRAF2 islets
---------------------------------------------------------------------------

In a second approach to establish the β cell--intrinsic defect, we challenged βTRAF2 islets in a GSIS assay. βTRAF2 islets exhibited normal basal insulin output at a glucose concentration of 2 mM ([Fig. 4 E](#fig4){ref-type="fig"}). However, when challenged with 20 mM glucose, βTRAF2 islets exhibited a 50% decrease in GSIS compared with WT islets. KCl, which induces membrane depolarization to trigger insulin secretion independent of glucose, provoked a normal insulin secretory response in βTRAF2 islets, indicating that insulin content and secretory machinery were intact in these NIK-activated islets. Collectively, the in vivo transplant and GSIS data demonstrate that the metabolic defect observed for βTRAF2 mice is β cell intrinsic.

Destabilizing the TRAF2--TRAF3--BIRC2/3 E3 ligase complex results in impaired β cell function
---------------------------------------------------------------------------------------------

The β cell secretory defect in βTRAF2 mice suggests that β cell--intrinsic NIK activation results in impaired β cell function. A potential caveat to this interpretation is that TRAF2 is also necessary for molecular control over the canonical NF-κB and JNK/activator protein 1 (AP-1) signaling pathways ([@bib58]). While TRAF2 and TRAF3 are both required to suppress NIK activity, TRAF3 differs from TRAF2 as it is not involved in NF-κB and JNK/AP-1 signaling downstream of TNFR family members ([@bib51]). Therefore, we examined NIK activation and β cell function in β cell--specific TRAF3 knockout (βTRAF3) mice. βTRAF3 islets showed reduced mRNA and protein levels of TRAF3 compared with WT islets ([Fig. 5, A and B](#fig5){ref-type="fig"}). TRAF3-deficient islets showed constitutive, cell-intrinsic hyperaccumulation of NIK, higher levels of phospho-IKKα, an increased p52 to p100 ratio and increased RelB levels ([Fig. 5 C](#fig5){ref-type="fig"}). Canonical NF-κB and JNK signaling in response to TNF, however, was normal in pancreatic islets lacking TRAF3 (unpublished data), as has been described in other cell types ([@bib19]).

![**Destabilization of the TRAF2-TRAF3-BIRC2/3 E3 ligase complex results in impaired β cell function.** (A) TRAF3 protein levels in WT and βTRAF3 islets from one WT and one βTRAF3 mouse were assessed by immunoblotting. A representative of three independent islet isolates tested per genotype is shown. Histogram data depict mean and SEM cumulative densitometry relative to β-actin of the three independent experiments. (B) Relative expression of islet TRAF3 mRNA in six WT and three βTRAF3 islet isolates was determined by RT-PCR. Data are representative of two independent experiments. \*\*\*, P \< 0.001. (C) Protein levels of NIK, IKKα/β phosphorylation, IκBα, p100 to p52 processing, and RelB in one nonstimulated WT and one βTRAF3 islet isolate were assessed by immunoblotting. A representative of three independent experiments is shown. Histogram data depict cumulative densitometry relative to β-actin of the three independent experiments. (D) Non-fasted blood glucose levels were determined in 20 TRAF3~loxP/loxP~ (WT) and 12 βTRAF3 chow-fed mice (8 wk old; n.s.); in 20 TRAF3~loxP/loxP~ (WT) and 10 βTRAF3 chow-fed mice at 16 wk old (n.s.); and in 15 TRAF3~loxP/loxP~ (WT) and 12 βTRAF3 HFD-fed mice (16 wk old). \*, P \< 0.05. Data are representative of three independent mouse cohorts tested. (E) Blood glucose levels were measured in 20 TRAF3~loxP/loxP~ (WT) and 10 βTRAF3 chow-fed mice (16 wk old) after i.p. injection of [d]{.smallcaps}-glucose (WT, dotted line; βTRAF3, solid line). Data are representative of three independent mouse cohorts tested. \*\*\*, P \< 0.001. (F) Insulin levels were measured in six TRAF3~loxP/loxP~ (WT) and six βTRAF3 chow-fed mice (16 wk old) after i.v. injection of [d]{.smallcaps}-glucose (WT: dotted line; βTRAF3: solid line). Data are representative of three independent mouse cohorts tested. \*, P \< 0.05 at 20 min after injection. (G) Blood glucose levels were measured in 15 TRAF3~loxP/loxP~ (WT), 5 RI Cre (WT) and 12 βTRAF3 chow-fed mice (16 wk old) after i.p. injection of [d]{.smallcaps}-glucose (WT, dotted line; βTRAF3, solid line). Data are representative of three independent mouse cohorts tested. \*\*\*, P \< 0.001. (H) Insulin levels were measured in 10 TRAF3~loxP/loxP~ (WT), 5 RI Cre, and 8 βTRAF3 HFD-fed mice (16 wk old) after i.v. injection of [d]{.smallcaps}-glucose (WT, dotted line; βTRAF3, solid line). Data are representative of three independent mouse cohorts tested. \*, P \< 0.05. (I) Pancreatic insulin content in HFD-fed WT and βTRAF3 mice was determined. The data are mean and SEM derived from five mice per group (n.s.; P = 0.072). (J) Total β cell area was determined for HFD-fed WT and βTRAF3 mice by quantification of insulin-positive area in serial graft sections as a percentage of total pancreatic exocrine tissue. The data are mean and SEM derived from three mice per group. \*, P \< 0.05. (K) In vitro GSIS in 2, 11, and 20 mM [d]{.smallcaps}-glucose. KCl conditions in WT and βTRAF3 mouse islets were measured. Data are mean and SEM derived from six independent islet isolates for each group and are representative of two independent experiments. \*, P \< 0.05. All data are represented as mean ± SEM; p-values were determined using Student's *t* test.](JEM_20150218_Fig5){#fig5}

Chow-fed βTRAF3 mice exhibited normal weight increase, normal glucose tolerance at 8 wk of age (not depicted), and normal nonfasted blood glucose levels ([Fig. 5 D](#fig5){ref-type="fig"}), but they displayed mildly decreased glucose tolerance and insulin secretion at 16 wk of age compared with WT mice ([Fig. 5, E and F](#fig5){ref-type="fig"}). In a DIO model, βTRAF3 mice presented with abnormally high nonfasted blood glucose levels ([Fig. 5 D](#fig5){ref-type="fig"}), impaired glucose tolerance ([Fig. 5 G](#fig5){ref-type="fig"}), and a reduction in GSIS in vivo compared with WT mice ([Fig. 5 H](#fig5){ref-type="fig"}). Analysis of total pancreatic insulin content and β cell mass revealed that DIO βTRAF3 mice exhibited increased pancreatic insulin content compared with WT mice due to an increase in their β cell area ([Fig. 5, I and J](#fig5){ref-type="fig"}). Further to this, βTRAF3 islets showed reduced GSIS ex vivo but a normal insulin secretory response to KCl ([Fig. 5 K](#fig5){ref-type="fig"}). Thus, βTRAF3 mice phenocopy βTRAF2 mice with β cell--intrinsic NIK hyperactivation and impaired β cell function.

Loss of BIRC proteins results in impaired β cell function
---------------------------------------------------------

The key role of TRAF2 and TRAF3 in regulation of NIK is the recruitment and directed control of the E3 ligase activity of BIRC proteins toward NIK. As MV1-induced NIK activation occurs through BIRC2 and BIRC3 degradation, we hypothesized genetic ablation of BIRC2 and BIRC3 in β cells would trigger a β cell defect. Mice that lack both BIRC2 and BIRC3 in their β cells (βBIRC2/3) exhibit islet-intrinsic NIK hyperactivation, as indicated by increased p100 processing ([Fig. 6 A](#fig6){ref-type="fig"}) with impaired glucose tolerance and reduced insulin secretion in a DIO model ([Fig. 6, B and C](#fig6){ref-type="fig"}). These data demonstrate that all components of the TRAF2--TRAF3--BIRC2--BIRC3 E3 ligase complex are required to provide the β cell protective circuit that reigns in the deleterious activation of NIK, which suggests that firm regulation of NIK in β cells is essential to control glucose sensing and insulin secretion. Further, these data demonstrate that NIK activation precipitates β cell failure in a DIO model.

![**Genetic ablation of BIRC2 and 3 phenocopies βTRAF2 and βTRAF3 mice.** (A) Protein levels of p100 to p52 processing in one WT and one βBIRC2/3 islet isolate were assessed by immunoblotting. A representative of three independent experiments is shown. Histogram data depicts cumulative densitometry relative to β-actin of the three independent experiments. (B) Blood glucose and AUC were measured in 20 WT and 6 βBIRC2/3 HFD-fed mice (16 wk old) after i.p. injection of [d]{.smallcaps}-glucose. Data are representative of three independent mouse cohorts tested. \*\*, P \< 0.01. (C) Insulin levels and AUC were measured in six WT and six βBIRC2/3 HFD-fed mice (16 wk old) after i.v. injection of [d]{.smallcaps}-glucose. Data are representative of three independent mouse cohorts tested. \*, P \< 0.05. All data are represented as mean ± SEM; p-values were determined using Student's *t* test.](JEM_20150218_Fig6){#fig6}

Expression profiling of βTRAF2 and βTRAF3 islets reveals a diabetes gene signature
----------------------------------------------------------------------------------

To determine the molecular basis for islet dysfunction, we determined genes that were differentially expressed in both βTRAF2 and βTRAF3 islets compared with WT islets using microarray analysis. We identified 26 differentially expressed genes common to the chow-fed βTRAF2 and βTRAF3 islets and 35 differentially expressed genes common to the DIO βTRAF2 and βTRAF3 islets compared with respective WT controls ([Fig. 7 A](#fig7){ref-type="fig"}). The 15 most differentially expressed genes within chow and DIO βTRAF2 and βTRAF3 islets comparing logarithmic fold change (logFC) and their function are listed in [Table 1](#tbl1){ref-type="table"} and [Table S1](http://www.jem.org/cgi/content/full/jem.20150218/DC1){#supp1}. Additionally, nine differentially expressed genes overlapped between the chow and DIO βTRAF2 and βTRAF3 islets ([Table 1](#tbl1){ref-type="table"}, top six most differentially expressed genes highlighted in bold). The majority of the differentially expressed genes were up-regulated in βTRAF2 and βTRAF3 islets. This indicates that NIK and the noncanonical NF-κB pathway activate rather than repress a select transcriptional program in pancreatic β cells. The up-regulation of *Tph1*,*Lrrc55*,*Hcn1*,*Tnfrsf11b*,*Rasgrp1*,*Grem2*, and*Pde7b* in βTRAF2 and βTRAF3 islets was validated by RT-PCR in a series of independent experiments ([Fig. 7 B](#fig7){ref-type="fig"}). Gene ontology analysis highlighted regulators of growth and proliferation, metabolic genes, potassium channel components, and vesicle-associated genes, many of which are associated with diabetes in animal models ([Table 2](#tbl2){ref-type="table"}). Significantly, many of the differentially expressed genes have been identified in human studies such as GWAS, linking genes such as *Bcat1* ([@bib22]; [@bib42]; [@bib30]; [@bib9]), *Gbp4* ([@bib54]), *Igfbp5* ([@bib28]; [@bib1]), *Kcnj5* ([@bib34]; [@bib12]; [@bib13]), *Matn2* ([@bib1]; [@bib12]), *Rerg*, *Rph3a*, *Slca13*, and *Pde7b* ([@bib13]), *Sftpd* ([@bib38]), *Rasgrp1* ([@bib41]; [@bib49]; [@bib33]), or *Tnfrsf11b* ([@bib37]; [@bib5]; [@bib12]) to type 1 and type 2 diabetes. These data identify NIK as a critical new β cell--intrinsic signaling node in diabetes integrating a transcriptional network that controls glucose homeostasis.

![**Differentially regulated genes and expression validation by RT-PCR in βTRAF2 and βTRAF3 islets.** (A) Venn diagram of the number of differentially regulated genes in βTRAF2 chow, βTRAF3 chow, βTRAF2 DIO, and βTRAF3 DIO mice compared with respective WT controls is shown. (B) A validation of gene microarray results was assessed by RT-PCR in βTRAF2 and βTRAF3 islets. The expression levels of *Tph1*, *Lrrc55*, *Hcn1*, *Tnfrsf11b* (OPG), *Rasgrp1*,*Grem2*, and *Pde7b* were examined in five βTRAF2 and five βTRAF3 islet isolates and are presented as a fold change relative to three TRAF2~loxP/loxP~ and three TRAF3~loxP/loxP~ (WT) islet isolates. Data are representative of two independent experiments. \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001. Data are represented as mean ± SEM; p-values were determined using Student's *t* test.](JEM_20150218_Fig7){#fig7}

###### 

Top 15 most highly differentially expressed genes in βTRAF2 and βTRAF3 islets (chow and DIO)

  Gene[a](#tblfn1){ref-type="table-fn"}                                       Log FC[b](#tblfn2){ref-type="table-fn"}   Associated function[c](#tblfn3){ref-type="table-fn"}                 
  --------------------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------ ------ ------ ------------------------------------------------------------------------------------------------------------------------------------------
  *Tph1* (tryptophan hydroxylase 1)                                           \-                                        \-                                                     6.88   6.33   aromatic amino acid family metabolic process, bone remodeling, neuron projection, serotonin synthesis
  *Lrrc55* (leucine rich repeat containing 55)                                3.78                                      2.90                                                   5.00   5.04   potassium ion transport, BK channel auxiliary subunit
  *Sftpd* (surfactant associated protein D)                                   3.12                                      2.28                                                   4.07   3.15   phospholipid homeostasis, regulation of phagocytosis, LPS binding
  *Gbp8* (guanylate-binding protein 8)                                        3.16                                      \-                                                     3.59   3.36   large IFN-γ--induced GTPase
  *Syt10* (synaptotagmin X)                                                   3.20                                      \-                                                     3.53   3.24   regulation of Ca^2+^-dependent exocytosis, cytoplasmic vesicle
  *Crispld2* (cysteine-rich secretory protein LCCL domain containing 2)       3.36                                      3.33                                                   \-     2.68   extracellular matrix (ECM) component, heparin binding, LPS binding, vesicle transport
  *Hcn1* (hyper-polarization-activated, cyclic nucleotide-gated K^+^ 1)       2.75                                      2.40                                                   3.36   3.24   potassium ion transport; voltage-gated potassium channel, sensitivity to cAMP
  *Fbxw24* (F-box and WD-40 domain protein 24)                                2.91                                      1.82                                                   3.48   2.99   protein coding gene, unknown function
  *Tnfrsf11b* (tumor necrosis factor receptor superfamily, member 11b)        \-                                        \-                                                     3.20   3.19   osteoprotegerin (OPG), ECM organisation, regulation of differentiation, negative regulation of bone resorption, decoy receptor for RANKL
  *Matn2* (matrilin 2)                                                        \-                                        \-                                                     3.42   2.92   ECM, formation of filamentous networks, neuron cell migration,Ca^2+^-binding,
  *Rerg* (RAS-like, estrogen-regulated, growth-inhibitor)                     2.13                                      1.56                                                   3.30   3.04   RAS superfamily of GTPases, negative regulator of cell growth/proliferation
  Rasgrp1(RAS guanyl releasing protein 1)                                     3.16                                      3.07                                                   \-     2.93   GEF activity: activation of Ras and Rho GTPases, Ca^2+^ binding
  Fmo1(flavin containing monooxygenase 1)                                     \-                                        \-                                                     3.16   2.55   drug metabolic process; oxidation-reduction process; NADPH oxidation; organic acid metabolic process
  *Grem2* (gremlin 2 homolog, cysteine knot superfamily (*Xenopus laevis*))   2.19                                      1.49                                                   2.54   2.28   regulator of osteoblast differentiation and osteogenesis; cytokine, heparin binding, negative regulation of BMP signaling pathway
  *Gbp4* (guanylate binding protein 4)                                        2.29                                      2.44                                                                 large IFN-γ--induced GTPase negative regulation of protein ubiquitination

Gene symbol and gene name.

Log fold change of differential gene expression in chow and DIO βTRAF2 and βTRAF3 islets.

Associated gene function according to DAVID Bioinformatics Database and Mouse Genome Database (MGD) at <http://www.informatics.jax.org> (September 2014).

###### 

Gene ontology and diabetes association of differentially expressed genes in βTRAF2 and βTRAF3 islets (chow and DIO)

                                                              chow                                                                                              DIO
  ----------------------------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  Gene ontology[a](#tblfn4){ref-type="table-fn"}                                                                                                                
  Regulation of cell growth, proliferation, apoptosis         *Adora1*, *Bcat1*, *Gfra3*, *Grem2*, *Rasgrp1*, *Rerg*, *Sftpd*, *Socs2*                          *Cish, Fmo1, Igfbp5, Ngfr, Prok1, Tph1, Tnfrsf11b*
  Metabolic processes                                         *Adora1, Bcat1, Grem2, Ogdhl, Slca13, Wipi1*                                                      *Fmo1, Ivd, Pde7b, Tph1, Srbd1*
  Potassium channel component                                 *Hcn1, Kcnk10, Lrrcc55*                                                                           *Hcn1, Kcnj5*
  GPCR or GTPase related                                      *Adora1, Gbp4, Gbp10, Gpr126, Gpr182, Penk, Rasgrp1*                                              *Cish, Gbp8, Gpr110, Kcnj5, Rph3a*
  Vesicle-associated                                          *Crispld2, Krtap13-1, Rasgrp1, Wipi1*                                                             *Rph3a, Syt10, Tmem2*
  Diabetes association[b](#tblfn5){ref-type="table-fn"}                                                                                                         
  associated with type 1 diabetic phenotype in mouse models   *Adora1, Bcat1, Gbp4, Gbp10, Hcn1, Rasgrp1*                                                       *Fmo1, Ngfr, Tnfrsf11b*
  associated with type 2 diabetic phenotype in mouse models   *Adora1, Bcat1, Gfra3, Gpr126, Hcn1, Kcnk10, Penk, Rasgrp1, Rerg, Sftpd, Socs2, Tnfrsf9, Wipi1*   *B3galnt1, B3galt1, Cish, Cym, Fmo1, Igfbp5, Kcnj5, Ngfr, Tnfrsf11b*
  associated with T1D in humans                               *Gbp4, Rasgrp1*                                                                                   *Igfbp5, Tnfrsf11b*
  associated with T2D in humans                               *Bcat1, Rasgrp1, Sftpd*                                                                           *Adarb2, Igfbp5, Ivd, Kcnj5, Pde7b, Rerg, Rph3a, Slca13, Tnfrsf11b*

Genes grouped by associated biological function according to DAVID Bioinformatics Database.

Genes associated with T1D and/or T2D in humans; genes associated with a diabetic phenotype in mouse models.

DISCUSSION
==========

We have identified NIK as a novel mechanism of β cell dysfunction in obesity. Acute NIK activation using a pharmacological approach disrupts glucose homeostasis in a zebrafish model, and induces β cell dysfunction in mouse islets, but also in human islets, highlighting the importance of the NIK pathway in human islet physiology as a negative regulator of β cell function. As we have demonstrated, pancreatic β cells in a model of obesity and glucose intolerance present with β cell--intrinsic NIK activation and a decrease in β cell insulin secretory capacity. We could demonstrate that NIK was induced by inflammatory cytokines TNF and RANKL in pancreatic mouse islets. Both cytokines constitute good candidates as NIK activators in a DIO mouse model and in human obesity. Both RANKL and TNF levels are elevated in mouse models of obesity and in T2D subjects ([@bib26]; [@bib31]). Blockade of TNF or RANKL improved glucose tolerance in mouse models of obesity ([@bib50]; [@bib31]). Further, TNF inhibition has been shown to alleviate the metabolic syndrome in several human studies ([@bib3]; [@bib35]; [@bib7]).

Our data furthers studies showing that diet-induced obesity induces NIK in peripheral insulin-dependent tissues such as liver ([@bib46]) and muscle ([@bib11]). Further evidence for a crucial involvement of NIK in whole body glucose homeostasis comes from studies of NIK knockout mice, which are hypoglycemic and exhibit improved glucose tolerance on a chow diet ([@bib46]). Accumulation of NIK is associated with decreased glucose uptake in muscle ([@bib11]) and increased hepatic glucose output by the liver ([@bib46]). Thus, NIK is emerging as a global molecular factor in obesity, therefore, these data highlight the possibility of systemic NIK inhibition as a potential therapeutic target to reduce hepatic glucose production and improve muscle uptake of glucose, while simultaneously preserving β cell function.

As we showed for pancreatic islets in diet-induced obesity, NIK levels are increased in the livers of genetically (*db/db)* and diet-induced obese mice ([@bib46]). Hepatocyte-specific NIK overexpression increased hepatic glucose output, presumably by phosphorylation and concomitant elevation and activation of the transcription factor cAMP response element-binding (CREB) levels, which stimulates gluconeogenesis. This process is controlled by cAMP-dependent PKA phosphorylating and activating CREB. We identified *Pde7b* as a highly expressed gene in islets with constitutively activated NIK (βTRAF2 and βTRAF3 islets). *Pde7b*, which encodes for phosphodiesterase 7b (PDE7B), is involved in the conversion of cAMP to AMP, thereby decreasing cAMP secondary messenger activity ([@bib25]). cAMP regulates glucose sensing and insulin secretion in pancreatic β cells, through both PKA-dependent and-independent mechanisms ([@bib2]; [@bib32]). Significantly, *Pde7b* and *Traf2* were both recently shown to be differentially methylated in a genome-wide analysis of human T2D pancreatic islets ([@bib13]). *Pde7b* was found to be differentially expressed in human T2D pancreatic islets as assessed by RT-PCR, and its overexpression caused a reduction in glucose-stimulated insulin secretion in vitro ([@bib13]). This suggests that overactivation of NIK may provide a direct link between regulation of cAMP levels and CREB activity, both in liver and in islets.

Inflammation has emerged as a key factor in the pathogenesis of the metabolic syndrome acting at the level of muscle and liver to induce insulin resistance, at adipocytes to drive elaboration of cytokines, and at the level of the β cell. Key signaling pathways include the JNK and canonical NF-κB pathways. Here, we demonstrate NIK levels are elevated in pancreatic islets isolated from diet-induced obese mice, which exhibited decreased insulin secretory capacity. Further, several genetic mouse models of constitutive β cell--intrinsic NIK activation present impaired glucose-stimulated insulin secretion in diet-induced obesity. Thus, NIK acts as a critical signaling node that regulates a transcriptional network to control glucose homeostasis. NIK activation in obesity is a feature of pancreatic β cells, liver and muscle providing a tissue-spanning mechanistic understanding of the global effects of obesity in the metabolic syndrome.

MATERIALS AND METHODS
=====================

### Mouse strains.

C57BL/6 mice were sourced from Australian BioResource (Mossvale, NSW, Australia). TRAF2~loxP/loxP~, TRAF3~loxP/loxP~ (C57BL/6 background; gift from R. Brink, Garvan Institute, NSW, Australia) and Birc3^−/−^ mice containing Birc2~loxP/loxP~ (C57BL/6 background; gift from D. Vaux, Walter and Eliza Hall Institute, VIC, Australia) were crossed with RIP-Cre mice (Cre driven by the rat insulin 2 promoter; Tg\[Ins2-cre\]25Mgn/J, C57BL/6 background; The Jackson Laboratory) to generate β cell--specific knockout mice (βTRAF2, βTRAF3, and βBIRC2/3).

### Zebrafish studies.

WT zebrafish larvae were injected pericardially at 6 d after fertilization with 2 nl of 10 mM MV1 in 10% DMSO or 10% DMSO as described ([@bib24]). Free glucose levels were analyzed 6 h after injection using a fluorescent glucose assay kit (Biovision; [@bib29]).

### In vivo studies.

For islet transplantation, 150 hand-counted primary islet equivalents isolated from male and female donor mice were transplanted into syngeneic diabetic male C57BL/6 recipients as previously described ([@bib21]). Mice in the DIO model were fed a diet providing 45% calories from fat (lard/safflower oil) ad libitum. Glucose tolerance tests (i.p. 2 g/kg and i.v. 1 g/kg body weight) after a 16-h fast were performed on female βTRAF2, βTRAF3, and βBIRC2/3 mice and respective floxed and RIP Cre controls mice as previously described ([@bib8]). Blood samples for insulin ELISA (mouse ultra-sensitive kit; Crystal Chem) were collected using 5-µl micro-capillary tubes (Drummond microcaps; Sigma-Aldrich). Insulin secretory capacity was determined by normalizing insulin levels or insulin secretion measured by AUC to total β cell area. Islets were isolated as previously described ([@bib60]), from male and female donors for GSIS, RNA extraction, and Western blot protein extraction. In vivo mouse physiology experiments comprise data from at least three independent cohorts.

### Analysis of TRAF2 and TRAF3 mRNA expression in isolated islets.

Isolated mRNA (QIAschredder, RNEasy Plus Mini kit; QIAGEN) was reverse transcribed (Quantitect Reverse Transcription kit; QIAGEN). mRNA expression was determined by Real Time-PCRs using FastStart SYBR Green Master Mix (Roche). PCR reactions were performed with the following primers and normalized to the house-keeping gene Cyclophillin A (CpH, sense 5′-TGGACCAAACACAAACGGTTCC-3′ and antisense 5′-ACATTGCGAGCAGATGGGGTAG-3′; TRAF2, sense 5′-TCTGCCTGACCAGCATCCTC-3′ and antisense 5′-AATGCCTTCTTCATACAGGCCTTC-3′; TRAF3, sense 5′-CAGCGTGCCAAGAAAGCATC-3′ and antisense 5′-CGCACAACCTCTGCCTTCAT-3′). Initial denaturation was performed at 95°C for 10 s, followed by a three step cycle consisting of 95°C for 15 s (4.8°C/s, denaturation), 63°C for 30 s (2.5°C/s, annealing), and 72°C for 30 s (4.8°C/s, elongation). A melt-curve was performed after finalization of 45 cycles at 95°C for 2 min, 40°C for 3 min, and gradual increase to 95°C with 25 acquisitions/°C.

### Assessment of signaling pathway activation.

Protein was extracted from islets or cell lines using a detergent-based lysis buffer. 30--40 µg of protein per well were separated on an SDS-PAGE and protein levels were determined by Western Blot analysis using the following antibodies (expected protein size \[kD\] is indicated): TRAF2 (C-20; 50 kD), TRAF3 (H-122; 65 kD; Santa Cruz Biotechnology Inc.), IκBα (39 kD), NIK (125 kD), phospho-IKKα/β (85/87 kD), p100/p52 (120 & 52kD), RelB (70 kD; Cell Signaling Technology), β-actin (42 kD; Sigma-Aldrich), anti--rabbit IgG (horseradish peroxidase-conjugated; Thermo Fisher Scientific), and anti--mouse IgG (and horseradish peroxidase-conjugated; Thermo Fisher Scientific). Signals were visualized using an enhanced chemiluminescence detection kit (Amersham Pharmacia Biotech). Western blot signals were quantified using the ImageJ (NIH) histogram function. Subsequently, the band intensity was normalized to relative protein concentration using β actin as a reference.

### Immunohistochemistry and β cell area determination.

Tissues were fixed in 10% buffered formalin and 5-µm paraffin sections were stained with hematoxylin-eosin. Serial consecutive sections in 100-µm intervals were stained for insulin (polyclonal anti--rabbit; Cell Signaling Technology) and counter-stained with hematoxylin. β cell area was assessed by determining total insulin-positive area (ImageJ).

### GSIS.

Three human pancreatic islet isolates were prepared at the St. Vincent's Hospital Centre for Islet Isolation (Melbourne, Australia) from heart-beating deceased donors. GSIS was determined for islets ex vivo as described ([@bib8]).

### Whole pancreas insulin content.

To determine whole pancreas insulin content, pancreata were collected and immediately immersed in ice-cold acidified ethanol. The tissue was homogenized with a tissue homogenizer (Heidolph Silent Crusher M) and total pancreatic insulin content was determined by insulin ELISA (mouse ultra-sensitive kit; Crystal Chem).

### Synthesis and purification of the MV1 compound.

The synthetic routes of MV1 production are available upon request.

### Microarray.

The quality of mRNA isolated from primary islets was evaluated by using an Agilent 2100 Bioanalyzer (Agilent Technologies). Samples were run in triplicates on a MoGene2.0 (GeneChip Mouse Gene 2.0 ST Array, Affymetrix) at the Ramaciotti Center (University of New South Wales, Australia). Raw data were deposited in the Gene Expression Omnibus database: accession no. [GSE68317](GSE68317).

### Statistical analysis.

Statistical analysis was performed using an unpaired two-tailed Students *t* test using Prism software (GraphPad Inc.). Error bars in all figures represent SEM as specified.

### Study approval.

Animal studies were approved by the Garvan/St Vincent's Animal Ethics Committee (AEC) fulfilling all the requirements of the NH&MRC and the NSW State Government. All procedures performed complied with the Australian Code of Practice for Care and Use of Animals for Scientific Purposes. This project was reviewed and approved by the St Vincent's Hospital (Melbourne, Australia) Human Research Ethics Committee: HREC-A 011/04.

### Online supplemental material.

Table S1 is a complete list of differentially expressed genes overlapping βTRAF2 and βTRAF3 islets (chow and DIO). Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20150218/DC1>.
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